Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 268

1.

Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model.

Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Li Wai Suen CS, Hofmann NE, Kinboro B, Waltmann A, Brewster J, Lorry L, Tarongka N, Samol L, Silkey M, Bassat Q, Siba PM, Schofield L, Felger I, Mueller I.

PLoS Med. 2015 Oct 27;12(10):e1001891. doi: 10.1371/journal.pmed.1001891. eCollection 2015 Oct.

2.

Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum.

Wampfler R, Hofmann NE, Karl S, Betuela I, Kinboro B, Lorry L, Silkey M, Robinson LJ, Mueller I, Felger I.

PLoS Negl Trop Dis. 2017 Jul 21;11(7):e0005753. doi: 10.1371/journal.pntd.0005753. eCollection 2017 Jul.

3.

Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial.

Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, Assef A, Kassa M, Chatfield MD, Landman KZ, Chenet SM, Lucchi NW, Udhayakumar V, Zhou Z, Shi YP, Kachur SP, Jima D, Kebede A, Solomon H, Mekasha A, Alemayehu BH, Malone JL, Dissanayake G, Teka H, Auburn S, von Seidlein L, Price RN.

PLoS Med. 2017 May 16;14(5):e1002299. doi: 10.1371/journal.pmed.1002299. eCollection 2017 May. Erratum in: PLoS Med. 2018 Oct 4;15(10):e1002677.

4.

UK malaria treatment guidelines 2016.

Lalloo DG, Shingadia D, Bell DJ, Beeching NJ, Whitty CJM, Chiodini PL; PHE Advisory Committee on Malaria Prevention in UK Travellers.

J Infect. 2016 Jun;72(6):635-649. doi: 10.1016/j.jinf.2016.02.001. Epub 2016 Feb 12.

PMID:
26880088
5.

Primaquine treatment for Plasmodium vivax--an essential tool for malaria control and elimination in Papua New Guinea.

Betuela I, Robinson LJ, Hetzel MW, Laman M, Siba PM, Bassat Q, Mueller I.

P N G Med J. 2014 Mar-Dec;57(1-4):68-74.

PMID:
26930890
6.

Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.

Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, Del Portillo HA, Siba P, Alonso PL, Bassat Q, Mueller I.

J Infect Dis. 2012 Dec 1;206(11):1771-80. doi: 10.1093/infdis/jis580. Epub 2012 Sep 10.

PMID:
22966124
7.

Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo.

Adekunle AI, Pinkevych M, McGready R, Luxemburger C, White LJ, Nosten F, Cromer D, Davenport MP.

PLoS Negl Trop Dis. 2015 Mar 17;9(3):e0003595. doi: 10.1371/journal.pntd.0003595. eCollection 2015 Mar.

8.

Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial.

Awab GR, Imwong M, Bancone G, Jeeyapant A, Day NPJ, White NJ, Woodrow CJ.

Am J Trop Med Hyg. 2017 Dec;97(6):1782-1787. doi: 10.4269/ajtmh.17-0290. Epub 2017 Oct 26.

9.

Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.

Campo B, Vandal O, Wesche DL, Burrows JN.

Pathog Glob Health. 2015 May;109(3):107-22. doi: 10.1179/2047773215Y.0000000013. Epub 2015 Apr 18. Review.

10.

In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.

Hwang J, Alemayehu BH, Reithinger R, Tekleyohannes SG, Takele Teshi, Birhanu SG, Demeke L, Hoos D, Melaku Z, Kassa M, Jima D, Malone JL, Nettey H, Green M, Poe A, Akinyi S, Udhayakumar V, Kachur SP, Filler S.

PLoS One. 2013 May 22;8(5):e63433. doi: 10.1371/journal.pone.0063433. Print 2013.

11.

Risk factors for Plasmodium falciparum and Plasmodium vivax gametocyte carriage in Papua New Guinean children with uncomplicated malaria.

Karl S, Laman M, Moore BR, Benjamin JM, Salib M, Lorry L, Maripal S, Siba P, Robinson LJ, Mueller I, Davis TM.

Acta Trop. 2016 Aug;160:1-8. doi: 10.1016/j.actatropica.2016.04.002. Epub 2016 Apr 4.

PMID:
27056132
12.

Therapeutic efficacy of chloroquine and chloroquine plus primaquine for the treatment of Plasmodium vivax in Ethiopia.

Yeshiwondim AK, Tekle AH, Dengela DO, Yohannes AM, Teklehaimanot A.

Acta Trop. 2010 Feb;113(2):105-13. doi: 10.1016/j.actatropica.2009.10.001. Epub 2009 Oct 14.

PMID:
19835832
13.

Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.

Gonzalez-Ceron L, Rodriguez MH, Sandoval MA, Santillan F, Galindo-Virgen S, Betanzos AF, Rosales AF, Palomeque OL.

Malar J. 2015 Oct 30;14:426. doi: 10.1186/s12936-015-0938-2.

14.

A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan.

Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, Rowland M.

PLoS One. 2008 Aug 6;3(8):e2861. doi: 10.1371/journal.pone.0002861.

15.

Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea.

Marfurt J, Müeller I, Sie A, Maku P, Goroti M, Reeder JC, Beck HP, Genton B.

Am J Trop Med Hyg. 2007 Nov;77(5):947-54.

PMID:
17984359
16.

Adding a single low-dose of primaquine (0.25 mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial.

Mwaiswelo R, Ngasala B, Jovel I, Aydin-Schmidt B, Gosling R, Premji Z, Mmbando B, Björkman A, Mårtensson A.

Malar J. 2016 Aug 26;15(1):435. doi: 10.1186/s12936-016-1430-3.

17.

Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea.

Genton B, Baea K, Lorry K, Ginny M, Wines B, Alpers MP.

P N G Med J. 2005 Sep-Dec;48(3-4):141-50.

PMID:
17212060
18.
19.

Artemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trial.

Laman M, Moore BR, Benjamin JM, Yadi G, Bona C, Warrel J, Kattenberg JH, Koleala T, Manning L, Kasian B, Robinson LJ, Sambale N, Lorry L, Karl S, Davis WA, Rosanas-Urgell A, Mueller I, Siba PM, Betuela I, Davis TM.

PLoS Med. 2014 Dec 30;11(12):e1001773. doi: 10.1371/journal.pmed.1001773. eCollection 2014 Dec.

20.

UK malaria treatment guidelines.

Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, Hill DR, Warrell DA, Bannister BA; HPA Advisory Committee on Malaria Prevention in UK Travellers.

J Infect. 2007 Feb;54(2):111-21. Epub 2007 Jan 9.

PMID:
17215045

Supplemental Content

Support Center